Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View BHVN analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1 year price objectives for Biohaven Pharmaceutical's shares. Their BHVN share price forecasts range from $146.00 to $177.00. On average, they expect the company's share price to reach $157.17 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

Biohaven Pharmaceutical's stock was trading at $137.81 at the beginning of 2022. Since then, BHVN shares have increased by 9.7% and is now trading at $151.17.
View the best growth stocks for 2022 here.

Biohaven Pharmaceutical saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 4,430,000 shares, a drop of 10.0% from the August 15th total of 4,920,000 shares. Based on an average daily volume of 661,600 shares, the short-interest ratio is presently 6.7 days. Currently, 7.1% of the company's stock are sold short.
View Biohaven Pharmaceutical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BHVN earnings forecast.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) issued its quarterly earnings data on Friday, August, 5th. The company reported ($6.21) earnings per share for the quarter, missing the consensus estimate of ($2.79) by $3.42. The firm had revenue of $215.08 million for the quarter, compared to the consensus estimate of $209.33 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $151.17.

Biohaven Pharmaceutical (NYSE:BHVN) has a market capitalization of $10.83 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($14.82) on an earnings per share basis.

The company employs 928 workers across the globe.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at (203) 404-0410 or via email at jennifer.porcelli@biohavenpharma.com.